Collaboration Agreement between Monogram and Pfizer Extended
18 Maio 2009 - 8:00AM
Business Wire
Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced that
its partner Pfizer Inc has exercised its right to extend the
Collaboration Agreement between Monogram and Pfizer.
�The adjustments to our collaboration with Pfizer strengthen the
platform for commercialization of Trofile and indicate Pfizer�s
ongoing support for Trofile, which is the clinically validated
method of selecting patients for CCR5 antagonists such as
Selzentry,� said William Young, Monogram Chief Executive Officer.
�We are pleased to be continuing our collaboration with Pfizer
outside of the U.S.�
Monogram and Pfizer have a collaboration aimed at making
Monogram�s Trofile assay available on a global basis in support of
Pfizer�s commercialization of Selzentry. The agreement has an
initial term that ends on December 31, 2009 and Pfizer has five
separate options, exercisable annually, to extend the agreement by
one year. With today�s announcement Pfizer has exercised the first
of these options to extend the agreement through December 31, 2010.
Through this collaboration Pfizer and Monogram make Trofile
available outside of the U.S.
Monogram has also given its consent to allow Pfizer to assign
the agreement to the new entity that is planned to be established
when GlaxoSmithKline plc and Pfizer merge their HIV businesses.
About Monogram
Monogram is advancing individualized medicine by discovering,
developing and marketing innovative products to guide and improve
treatment of serious infectious diseases and cancer. The Company's
products are designed to help doctors optimize treatment regimens
for their patients that lead to better outcomes and reduced costs.
The Company's technology is also being used by numerous
biopharmaceutical companies to develop new and improved anti-viral
therapeutics and vaccines as well as targeted cancer therapeutics.
More information about the Company and its technology can be found
on its web site at www.monogrambio.com.
Webcast Details
Monogram will provide an update on its business today at the 8th
Annual JMP Securities Research Conference at 11:30 a.m. Eastern
Time (8:30 a.m. Pacific Time). Access to live and archived audio of
the conference call will be available by following the appropriate
links at www.monogrambio.com and clicking on the �Investors/Media�
tab and then on the "Events & Webcasts" link provided on the
sidebar menu on the page. The information provided on the webcast
presentation is only accurate at the time of the conference, and
Monogram assumes no obligation to provide updated information
except as required by law.
Forward Looking
Statements
Certain statements in this press release are forward-looking,
including statements regarding the demand and outlook for our
products, including our Trofile assay, the impact of the planned
joint venture between Pfizer and GlaxoSmithKline, our projected use
of cash, our projected revenues. These forward-looking statements
are subject to risks and uncertainties and other factors, which may
cause actual results to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not
limited to: risks and uncertainties relating to the performance and
acceptance of our products; the growth in revenues from all
products, including Trofile, growth in deferred revenues; the size,
timing and success or failure of any clinical trials for CCR5
inhibitors, entry inhibitors or integrase inhibitors; our ability
to successfully conduct clinical studies on our expected timelines
and the results obtained from those studies; whether larger
confirmatory clinical studies will confirm the results of initial
studies; expected reliance on a few customers for the majority of
our revenues; the renewal of certain customer agreements, including
the Pfizer collaboration for the ex-US distribution of Trofile; the
impact of our expense reduction programs; our ability to retain and
hire key employees; the impact of competition; whether payers will
authorize reimbursement for our products and services and the
amount of such reimbursement that may be allowed; whether the FDA
or any other agency will decide to further regulate our products or
services, including Trofile; whether the draft guidance on
Multivariate Index Assays issued by the FDA will be subsequently
determined to apply to our current or planned products; whether we
will encounter problems or delays in automating our processes; the
ultimate validity and enforceability of our patent applications and
patents; the possible infringement of the intellectual property of
others; whether licenses to third party technology will be
available; whether we are able to build brand loyalty and expand
revenues; restrictions on the conduct of our business imposed by
the Pfizer, G.E. and other debt agreements; the impact of
additional dilution if our convertible debt is converted to equity
or restructured; and whether we will be able to raise sufficient
capital in the future to repay our convertible debt in the event it
is not converted to equity or restructured, and/or to maintain
operations, if required. For a discussion of other factors that may
cause actual events to differ from those projected, please refer to
our most recent annual report on Form 10-K and quarterly reports on
Form 10-Q, as well as other subsequent filings with the Securities
and Exchange Commission. We do not undertake, and specifically
disclaim any obligation, to revise any forward-looking statements
to reflect the occurrence of anticipated or unanticipated events or
circumstances after the date of such statements.
Trofile is a trademark of Monogram Biosciences, Inc. Selzentry
is a trademark of Pfizer Inc.
Monogram Technologies (NASDAQ:MGRM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Monogram Technologies (NASDAQ:MGRM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
